NCT01334892View on ClinicalTrials.gov

L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant (LT) Patients

PHASE2/PHASE3TerminatedINTERVENTIONAL

Enrollment

130

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

July 31, 2013

Study Completion Date

December 31, 2014

Conditions

Bronchiolitis Obliterans

Interventions

DRUG

Cyclosporine Inhalation Solution

Cyclosporin for inhalation twice daily

Trial Locations (1)

82166

PARI Pharma GmbH, Gräfelfing

Sponsors

Lead Sponsor

Pari Pharma GmbH

All Listed Sponsors

lead

Pari Pharma GmbH

INDUSTRY

NCT01334892 - L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant (LT) Patients | Biotech Hunter | Biotech Hunter